E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10037153 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy, versus placebo, of fortnightly doses of CDP870 (200mg and 400mg) administered subcutaneously in subjects with moderate to severe psoriasis as measured by the proportion of subjects achieving ≥75% decrease from baseline in the Psoriasis Area and Severity Index score (PASI75) and the proportion of subjects with a Psoriasis Global Assessment (PGA) rating ‘Clear’ or ‘Almost Clear’ at the end of the 12 week treatment period. |
|
E.2.2 | Secondary objectives of the trial |
1. To assess the safety and tolerability of the different dose regimens of CDP870 administered subcutaneously for 12 weeks versus placebo. 2. To assess the efficacy of the different dose regimens of CDP870 administered subcutaneously for 12 weeks versus placebo as measured by: • the time to onset of action, defined as the time to first ≥50% decrease and the time to first ≥75% decrease from baseline in PASI during the treatment period • the time to relapse after the 12 week treatment period • the proportion of subjects experiencing rebound during the 2 first months of follow-up • the change from baseline in the body surface area (BSA) affected by psoriasis at the end of the 12 week treatment period • the proportion of subjects achieving ≥90% decrease from baseline in PASI (PASI90) at the end of the 12 week treatment period • the proportion of subjects achieving ≥50% decrease from baseline in PASI (PASI50) at the end of the 12 week treatment period
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Adult men and women > 18 years 2. Chronic plaque psoriasis that have been stable for at least 3 months and that have been moderate to severe for at least 6 months 3. PASI ≥12 and BSA ≥10% 4. Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy 5. Subject able to understand the information provided to them and to give written informed consent for CDP870-040 6. Female subject either postmenopausal for at least one year, surgically incapable of childbearing, or effectively practising an acceptable method of contraception (oral or parenteral hormonal contraceptives; intrauterine device; barrier and spermicide. Abstinence is not an acceptable method). Subjects must agree to continue to use adequate contraception during the study and for 12 weeks after the last dose of CDP870.
|
|
E.4 | Principal exclusion criteria |
1. Erythrodermic, guttate, palmar or plantar, generalised pustular form of psoriasis 2. Infections 3. Positive hepatitis B surface antigen test and/or hepatitis C antibody test results 4. Positive human immunodeficiency virus (HIV) test result 5. Severe, progressive, and/or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease 6. Hepatic or renal dysfunction measured by hepatic enzymes (AST and ALT) greater than three times the upper limit of normal or seric creatinine higher than 2mg/100ml 7. Pregnancy and lactating female 8. White blood cell counts less than 4000/mm³ or more than 20000/mm³ 9. New York Heart Association (NYHA) class III-IV congestive heart failure 10. Systemic Lupus 11. History of significant adverse reaction to biological products or polyethylene glycol 12. History of tuberculosis
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The co-primary efficacy variables are the proportion of subjects achieving ≥75% decrease from baseline in the Psoriasis Area and Severity Index score (PASI75) and the proportion of subjects with a Psoriasis Global Assessment (PGA) rating ‘Clear’ or ‘Almost Clear’ at the end of the 12 week treatment period. The study will be declared successful if at least one of the two dose comparisons to placebo is statistically significant for both the PASI and the PGA endpoints. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as the date of lock of the database corresponding to the whole study (treatment and follow-up periods). At that time, interactions between the Sponsor and the Investigator(s) with possible impact on subject’s data have ended. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 12 |